Octavian Therapeutics Overview
- Year Founded
-
2017
- Status
-
Out of Business
- Employees
-
13
- Latest Deal Type
-
Liquidation
- Investors
-
1
Octavian Therapeutics General Information
Description
Developer of cannabinoid drugs and pharmaceutical products intended to combat inflammatory diseases, cancer, neurological disorders and pain management. The company develops prescription medicines targeting the endocannabinoid system using an ai-driven drug discovery platform and a library of over two thousand new chemical entities, enabling pharmaceutical companies to access novel small molecule treatments for debilitating neuropathic and visceral pain conditions.
Contact Information
Website
www.octavianrx.comCorporate Office
- Prama House
- 267 Banbury Road
- Oxford OX2 7HT
- England, United Kingdom
Corporate Office
- Prama House
- 267 Banbury Road
- Oxford OX2 7HT
- England, United Kingdom
Octavian Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Bankruptcy: Liquidation | 09-Jun-2026 | Completed | Bankruptcy: Liquidation | |||
| 4. IPO | 21-May-2021 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 28-Feb-2018 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 15-Mar-2017 | $12.3M | $12.3M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 10-Mar-2017 | Completed | Startup |
Octavian Therapeutics Comparisons
Industry
Financing
Details
Octavian Therapeutics Competitors (3)
One of Octavian Therapeutics’s 3 competitors is AXIM Biotechnologies, a Corporation company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AXIM Biotechnologies | Corporation | New York, NY | ||||
| Jazz Pharmaceuticals | Formerly VC-backed | Dublin, Ireland | ||||
| CV Sciences | Corporation | San Diego, CA |
Octavian Therapeutics Patents
Octavian Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025149460-A1 | Cannabinoid compositions | Inactive | 08-Jan-2024 |
Octavian Therapeutics Signals
Octavian Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| University of Oxford | University |
Octavian Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Octavian Therapeutics FAQs
-
When was Octavian Therapeutics founded?
Octavian Therapeutics was founded in 2017.
-
Where is Octavian Therapeutics headquartered?
Octavian Therapeutics is headquartered in Oxford, United Kingdom.
-
What is the size of Octavian Therapeutics?
Octavian Therapeutics has 13 total employees.
-
What industry is Octavian Therapeutics in?
Octavian Therapeutics’s primary industry is Drug Discovery.
-
Is Octavian Therapeutics a private or public company?
Octavian Therapeutics is a Private company.
-
What is Octavian Therapeutics’s current revenue?
The current revenue for Octavian Therapeutics is .
-
How much funding has Octavian Therapeutics raised over time?
Octavian Therapeutics has raised $46M.
-
Who are Octavian Therapeutics’s investors?
University of Oxford has invested in Octavian Therapeutics.
-
Who are Octavian Therapeutics’s competitors?
AXIM Biotechnologies, Jazz Pharmaceuticals, and CV Sciences are competitors of Octavian Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process